Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones

NEXT STORY
Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021
PREV STORY
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19

author_avatar
NASDAQ Market News

AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure

author_avatar
NASDAQ Market News

Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13

author_avatar
NASDAQ Market News